FGL1 (human) Matched Pair Detection Set

CHF 750.00
In stock
AG-46B-0013-KI011 SetCHF 750.00
More Information
Product Details
Synonyms Fibrinogen-like Protein 1; FGL-1; Hepatocyte-derived Fibrinogen-related Protein 1; HFREP-1; Hepassocin
Product Type Set
Application Set Quantitative ELISA

Detects human FGL1 in serum, plasma and cell culture supernatant.

Crossreactivity Human

Contains sufficient materials to run ELISAs on 5 x 96-well plates.

Sensitivity <0.050 ng/ml
Range 0.078 to 5 ng/ml
Sample Type Cell Culture Supernatant
Assay Type Sandwich
Detection Type Colorimetric
Kit Contains

1 vial standard protein (100ng) (lyophilized) [STD]

1 vial coating antibody (320µl) [COAT]

1 vial detection antibody (70µl) [DET]

1 vial streptavidin-HRP (10µg) (lyophilized) [STREP]

Other Product Data

UniProt link Q08830: FGL1 (human)

Accession Number Q08830
Shipping and Handling
Shipping BLUE ICE
Short Term Storage -20°C
Long Term Storage -20°C
Handling Advice After standard reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
Manual Download PDF
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

FGL1 (Fibrinogen-like protein 1, also called Hepatocyte-derived fibrinogen-related protein 1, HFREP-1 or Hepassocin) was initially identified as an overexpressed transcript in hepatocyte carcinoma and as a transcript enriched in regenerating liver. FGL1 is expressed at lower levels in brown and white adipose in the setting of liver injury. A low level expression of FGL1 is also observed in the pancreas. FGL1 is a 34kDa protein structurally similar to Angiopoietin-like factors 2, 3, 4 and 6, which regulate lipid metabolism and energy utilization. It was proposed that FGL1 is a member of an emerging group of proteins having potential roles in liver metabolism and liver regeneration. Recently, FGL1 has also been shown to be upregulated in human cancers and FGL1 is a major functional ligand of LAG-3. FGL1 interacts with LAG-3 in a MHC-II-independent manner and this interaction involves the FGL1 fibrinogen-like domain and the LAG-3 D1-D2 domain. FGL1-LAG-3 interaction blockade promotes tumor immunity by stimulating T cell expansion and activation. FGL1 forms two disulfide-linked homodimers and also higher molecular weight homooligomers that bind to LAG-3 much better than the dimeric forms. This binding to LAG-3 inhibits T cell responses. FGL1 is highly produced by human cancer cells, and elevated FGL1 in the plasma of cancer patients is associated with a poor prognosis and resistance to anti-PD-1/ B7-H1 therapy.

Product References
  1. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3: J. Wang, et al.; Cell 176, 334 (2019) (General Reference)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.